Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

托法替尼（泛JAK抑制剂）与鲁索替尼（JAK1/2抑制剂）联合用于治疗伴有JAK3突变的难治性T细胞前淋巴细胞白血病（T-PLL）。